TY - JOUR
T1 - Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease
AU - Drudi, Laura M.
AU - Schaller, Melinda S.
AU - Hiramoto, Jade
AU - Gasper, Warren
AU - Harris, William S.
AU - Hills, Nancy K.
AU - Grenon, S. Marlene
N1 - Funding Information:
Funding sources: This work was supported by start-up funds from the University of California San Francisco and the Northern California Institute for Research and Education . The project described was supported by Award Number KL2RR024130 from the National Center for Research Resources, Award Number 1K23HL122446-01 from the National Institute of Health/NHLBI, and a Society for Vascular Surgery Seed Grant and Career Development Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The funding organizations were not involved in the design and conduct of the study, collection, management, analysis, and interpretation of the data, or preparation, review, or approval of the article. This publication was also supported by the National Center for Advancing Translational Sciences , National Institutes of Health , through UCSF-CTSI Grant Number ULI TR000004 . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. The authors would also like to thank Nordic Naturals for donation of the treatment and placebo capsules.
Publisher Copyright:
© 2016
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background The omega-3 index represents the red blood cell (RBC) content of two major long-chain n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid, and docosahexaenoic acid. We sought to determine factors associated with a favorable response to fish oil treatment and to characterize changes in RBC PUFAs associated with fish oil supplementation. Methods This study was a secondary analysis of the OMEGA-PAD I trial, a randomized, double-blinded, placebo-controlled trial investigating short-duration, high-dose n-3 PUFA oral supplementation on endothelial function and inflammation in subjects with peripheral arterial disease. Patients with mild to severe claudication received either 4.4 g of fish oil providing 2.6 g of eicosapentaenoic acid and 1.8 g of docosahexaenoic acid daily (n = 40) or placebo capsules (n = 40) for 1 mo. The RBC fatty acid content was measured by gas chromatography and expressed as a percent of total fatty acids. The change in omega-3 index was calculated as the difference between pre- and post-supplementation in the fish oil and placebo groups. Univariate analysis identified predictors of change in omega-3 index, with these variables included in our multivariable model. Results In the fish oil group, there was an increase in the omega-3 index (5.1± 1.3% to 9.0± 1.8%; P < 0.0001), whereas there was no change in the control group. Factors associated with a favorable response (i.e., greater than the median change of 4.06%) included a lower body mass index and higher concentrations of low-density lipoproteins. Other demographic and/or lifestyle factors such as age, race, or smoking status were unrelated to the response. Oral n-3 PUFA supplementation also decreased the n-6 PUFA content in RBCs. Conclusions Short-term, high-dose n-3 PUFA supplementation increases the omega-3 index to a greater extent in patients with a lower body mass index and higher total and low-density lipoprotein cholesterol levels.
AB - Background The omega-3 index represents the red blood cell (RBC) content of two major long-chain n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid, and docosahexaenoic acid. We sought to determine factors associated with a favorable response to fish oil treatment and to characterize changes in RBC PUFAs associated with fish oil supplementation. Methods This study was a secondary analysis of the OMEGA-PAD I trial, a randomized, double-blinded, placebo-controlled trial investigating short-duration, high-dose n-3 PUFA oral supplementation on endothelial function and inflammation in subjects with peripheral arterial disease. Patients with mild to severe claudication received either 4.4 g of fish oil providing 2.6 g of eicosapentaenoic acid and 1.8 g of docosahexaenoic acid daily (n = 40) or placebo capsules (n = 40) for 1 mo. The RBC fatty acid content was measured by gas chromatography and expressed as a percent of total fatty acids. The change in omega-3 index was calculated as the difference between pre- and post-supplementation in the fish oil and placebo groups. Univariate analysis identified predictors of change in omega-3 index, with these variables included in our multivariable model. Results In the fish oil group, there was an increase in the omega-3 index (5.1± 1.3% to 9.0± 1.8%; P < 0.0001), whereas there was no change in the control group. Factors associated with a favorable response (i.e., greater than the median change of 4.06%) included a lower body mass index and higher concentrations of low-density lipoproteins. Other demographic and/or lifestyle factors such as age, race, or smoking status were unrelated to the response. Oral n-3 PUFA supplementation also decreased the n-6 PUFA content in RBCs. Conclusions Short-term, high-dose n-3 PUFA supplementation increases the omega-3 index to a greater extent in patients with a lower body mass index and higher total and low-density lipoprotein cholesterol levels.
KW - Fish oil
KW - Omega-3 index
KW - Peripheral artery disease
KW - n-3 polyunsaturated fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85002169325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002169325&partnerID=8YFLogxK
U2 - 10.1016/j.jss.2016.11.011
DO - 10.1016/j.jss.2016.11.011
M3 - Article
C2 - 28457318
AN - SCOPUS:85002169325
SN - 0022-4804
VL - 210
SP - 124
EP - 131
JO - Journal of Surgical Research
JF - Journal of Surgical Research
ER -